LentiGlobin sickle cell

Shares of bluebird bio Inc (NASDAQ: BLUE) have gained more than 100 percent since the start of 2017 and, more recently, 40 percent on CAR-T "excitement." But now may be a time for investors to turn cautious, at least according to analysts at Morgan Stanley. The firm's Matthew Harrison downgraded...